Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature
- 26 August 2019
- journal article
- review article
- Published by BMJ in BMJ Case Reports
- Vol. 12 (8) , e229568
Abstract
Nivolumab is a programmed cell death receptor (PD-1) inhibitor that is increasingly used for various malignancies, both as a first line agent and as salvage therapy. Being a PD-1/PD-1 ligand checkpoint inhibitor, it is known to cause autoimmune inflammation of various organs and has been associated with thyroiditis, insulitis, colitis, hepatitis and encephalitis to name a few. There are increasing reports of nivolumab leading to acute onset fulminant type 1 diabetes and diabetic ketoacidosis (DKA). We present a case of a 68-year-old man who developed DKA after 2 doses of nivolumab for metastatic melanoma. He was found to have type 1 diabetes, but no diabetes related antibodies were positive. He recovered from diabetes and continues to use insulin 1 year after his diagnosis. This case and associated review illustrates the importance of educating and monitoring patients who start nivolumab therapy regarding this potentially life threatening complication.Keywords
This publication has 29 references indexed in Scilit:
- Management of toxicities of immune checkpoint inhibitorsCancer Treatment Reviews, 2016
- Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 DiabetesThe Tohoku Journal of Experimental Medicine, 2016
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and futureJournal of Clinical Investigation, 2015
- CTLA-4 as a genetic determinant in autoimmune Addison’s diseaseGenes & Immunity, 2015
- Precipitation of Autoimmune Diabetes With Anti-PD-1 ImmunotherapyDiabetes Care, 2015
- Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disordersCurrent Opinion in Pediatrics, 2013
- Class II HLA genotype in fulminant type 1 diabetes: A nationwide survey with reference to glutamic acid decarboxylase antibodiesJournal of Diabetes Investigation, 2011
- Deficiency in B7-H1 (PD-L1)/PD-1 Coinhibition Triggers Pancreatic β-Cell Destruction by Insulin-Specific, Murine CD8 T-CellsDiabetes, 2010
- Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetesProceedings of the National Academy of Sciences, 2005
- The Cellular Mechanism of Aire Control of T Cell ToleranceImmunity, 2005